Literature DB >> 17134111

Molecular pathogenesis of primary central nervous system lymphoma.

Cigall Kadoch1, Patrick Treseler, James L Rubenstein.   

Abstract

Primary central nervous system lymphoma (PCNSL) is an aggressive form of non-Hodgkin lymphoma (NHL) typically associated with a worse prognosis than other localized extranodal lymphomas with similar histological characteristics. The defining feature of PCNSL is its confinement to the central nervous system (CNS), with proclivity for growth within the leptomeningeal as well as intraocular compartments. Primary CNS lymphoma rarely disseminates outside the CNS and accounts for less than 5% of all primary brain neoplasms. At least 95% of PCNSLs are of large B-cell histology, the most common subtype of NHL. Consistent with the trend seen in systemic NHLs, the incidence of PCNSL has markedly increased over the past three decades, both in immunocompromised and immunocompetent patients. Because PCNSL is relatively rare, the identification of molecular prognostic biomarkers and the definition of a standard therapeutic strategy have been challenging. The authors discuss the current knowledge of the molecular pathogenesis of CNS lymphomas and review the recent advances in gene expression profile analysis and identification of novel prognostic biomarkers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17134111     DOI: 10.3171/foc.2006.21.5.2

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  13 in total

Review 1.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 2.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

Review 3.  Novel approaches to treating leptomeningeal metastases.

Authors:  Jai Grewal; Marlon Garzo Saria; Santosh Kesari
Journal:  J Neurooncol       Date:  2011-08-28       Impact factor: 4.130

4.  Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.

Authors:  Leslie L Muldoon; Seth J Lewin; Edit Dósa; Dale F Kraemer; Michael A Pagel; Nancy D Doolittle; Edward A Neuwelt
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

5.  Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma.

Authors:  Noriyasu Hashida; Nobuyuki Ohguro; Kohji Nishida
Journal:  Transl Vis Sci Technol       Date:  2012-10-22       Impact factor: 3.283

Review 6.  Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment.

Authors:  James Rubenstein; Andrés J M Ferreri; Stefania Pittaluga
Journal:  Leuk Lymphoma       Date:  2008

7.  Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.

Authors:  Cigall Kadoch; Eduard B Dinca; Ramona Voicu; Lingjing Chen; Diana Nguyen; Seema Parikh; Juliana Karrim; Marc A Shuman; Clifford A Lowell; Patrick A Treseler; C David James; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 8.  Insights into the biology of primary central nervous system lymphoma.

Authors:  Maciej M Mrugala; James L Rubenstein; Maurilio Ponzoni; Tracy T Batchelor
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

9.  Primary T-cell CNS lymphoma presenting with leptomeningeal spread and neurolymphomatosis.

Authors:  Netta Levin; Dov Soffer; Sigal Grissaru; Natasha Aizikovich; J Moshe Gomori; Tali Siegal
Journal:  J Neurooncol       Date:  2008-07-01       Impact factor: 4.130

Review 10.  Leptomeningeal disease: current diagnostic and therapeutic strategies.

Authors:  Gautam Nayar; Tiffany Ejikeme; Pakawat Chongsathidkiet; Aladine A Elsamadicy; Kimberly L Blackwell; Jeffrey M Clarke; Shivanand P Lad; Peter E Fecci
Journal:  Oncotarget       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.